scholarly journals Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma

2010 ◽  
Vol 2 (1) ◽  
pp. 4 ◽  
Author(s):  
Xi-Bao Zhang ◽  
San-Quan Zhang ◽  
Chang-Xing Li ◽  
Zhen-Ming Huang ◽  
Yu-Wu Luo
Biomedicines ◽  
2020 ◽  
Vol 8 (6) ◽  
pp. 156
Author(s):  
Terenzio Cosio ◽  
Monia Di Prete ◽  
Elena Campione

The treatment of advanced basal cell carcinoma has seen a progressive evolution in recent years following the introduction of Hedgehog pathway inhibitors. However, given the burden of mutations in the tumor microenvironment and lack of knowledge for the follow-up of advanced basal cell carcinoma, we are proposing a possible synergistic therapeutic application. Our aim is to underline the use of arsenic trioxide, itraconazole, all-trans-retinoic acid and nicotinamide as possible adjuvant therapies either in advanced not responding basal cell carcinoma or during follow-up based on Hedgehog pathway. We have analyzed the rational use of these drugs as a pivotal point to block neoplasm progression, modulate epigenetic modification and prevent recurrences.


Author(s):  
Victoria L. Wade ◽  
Winslow G. Sheldon ◽  
James W. Townsend ◽  
William Allaben

Sebaceous gland tumors and other tumors exhibiting sebaceous differentiation have been described in humans (1,2,3). Tumors of the sebaceous gland can be induced in rats and mice following topical application of carcinogens (4), but spontaneous mixed tumors of basal cell origin rarely occur in mice.


2000 ◽  
Vol 39 (5) ◽  
pp. 397-398 ◽  
Author(s):  
Hyoung-Joo Kim ◽  
Youn-Soo Kim ◽  
Ki-Beom Suhr ◽  
Tae-Young Yoon ◽  
Jeung-Hoon Lee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document